ABSTRACT

The review focuses on studying how to create, improve, and test a new type of treatment that combines liposomes (tiny fat-like particles) containing Amphotericin B (an antifungal medication) with an in situ vaginal gel. The goal of this innovative approach is to treat fungal infections, especially vulvovaginal candidiasis (a common yeast infection affecting the vaginal area). Amphotericin B, a potent antifungal medication, is highly effective against a wide range of fungal infections. However, its use is often restricted because it can cause harmful side effects when it spreads throughout the body (systemic toxicity) and is not well absorbed when taken using standard methods (poor bioavailability). This makes it challenging to use Amphotericin B effectively without causing unwanted health issues. Incorporating liposomes into an in- situ gel formulation addresses these challenges by enhancing drug encapsulation, providing sustained release, and improving mucosal adherence. The formulation aspects, such as the selection of polymers and surfactants, influence the gel’s sol-to-gel transition, viscosity, and mucoadhesive properties. This sentence explains that the formulation aims to treat fungal infections directly at the site of infection using a controlled and long-lasting delivery method. By doing this, the treatment can work more effectively and improve patient compliance (making it easier for patients to stick to the treatment). Considering the future, the plan is to further improve this formulation using advanced methods, explore its use for other types of vaginal infections, and carry out clinical trials to confirm that it works well and is safe for use. Keywords: Fungal infection, Amphotericin-B, Liposomes, In-situ ge
Publication date: 01/03/2026

https://ijbpas.com/pdf/2026/March/MS_IJBPAS_2026_9946.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.3.9946